Eckert & Ziegler to join Chinese-German pharma development joint venture
23-Jul-2013
- Germany
OctreoPharm Sciences has various peptides currently in pre-clinical development as a potential solution for the detection of neuroendocrine tumors using positron emission tomography (PET). Depending on the radionuclide it is coupled with, it could be used both in diagnosing (gallium-68) and treating (yttrium-90) such tumors. Clinical testing on humans (phase I) is slated to begin towards the end of next year.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.